PubRank

Amar P Dhillon

Author PubWeight™ 52.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Retraction of an interpretation. Lancet 2004 3.55
2 Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006 2.55
3 IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006 2.54
4 Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008 1.98
5 Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010 1.81
6 Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002 1.77
7 Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol 2012 1.65
8 Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. J Biomed Opt 2012 1.62
9 Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2005 1.62
10 Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005 1.58
11 The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology 2010 1.56
12 Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009 1.55
13 A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006 1.34
14 Scoring of chronic hepatitis. Clin Liver Dis 2002 1.25
15 Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 2007 1.24
16 Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002 1.24
17 Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011 1.10
18 Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007 1.09
19 Hepatic iron concentration, fibrosis and response to venesection associated with the A77D and V162del "loss of function" mutations in ferroportin disease. Blood Cells Mol Dis 2007 1.01
20 Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis 2011 0.99
21 Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006 0.98
22 The histogenesis of regenerative nodules in human liver cirrhosis. Hepatology 2010 0.93
23 Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int 2014 0.89
24 Severe, acute liver injury and khat leaves. N Engl J Med 2010 0.89
25 Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl 2011 0.87
26 HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2013 0.86
27 Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013 0.86
28 Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol 2002 0.85
29 Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2008 0.83
30 Xanthine oxidoreductase is present in bile ducts of normal and cirrhotic liver. Free Radic Biol Med 2004 0.82
31 Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biol Blood Marrow Transplant 2005 0.81
32 Hepatic steatosis estimated microscopically versus digital image analysis. Liver Int 2013 0.81
33 Fibrosis distribution in explanted cirrhotic livers. Histopathology 2012 0.80
34 Targeting of cholecystokinin B/gastrin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines. Int J Oncol 2006 0.80
35 A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008 0.80
36 Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl 2010 0.79
37 Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008 0.78
38 The use of guideline images to improve histological estimation of hepatic steatosis. Liver Int 2014 0.77
39 Validating non-invasive markers of fibrosis: the need for a new histological reference standard. Gut 2010 0.77
40 Noninvasive assessment of liver fibrosis: the clinical context and question are important. Hepatology 2011 0.77
41 Regression of fibrosis: the need for quantitative methods of assessment. J Hepatol 2012 0.76
42 Noninvasive assessment of liver fibrosis: the need for better validation. Hepatology 2011 0.76
43 Lack of agreement for defining 'clinical suspicion of rejection' in liver transplantation: a model to select candidates for liver biopsy. Transpl Int 2015 0.75
44 Noninvasive tests in the post-liver transplantation setting. Liver Transpl 2007 0.75
45 Length versus width in liver biopsies. J Hepatol 2006 0.75
46 A clinical and histopathologic perspective on evolving noninvasive and invasive alternatives for liver biopsy. Clin Gastroenterol Hepatol 2008 0.75
47 Endocytosis of anti-CCK-B/gastrin receptor antibody and effect on hepatoma cell lines. J Histochem Cytochem 2002 0.75
48 Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy? Oncol Rep 2005 0.75
49 Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates. Dig Dis Sci 2013 0.75